Karyopharm Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Karyopharm Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Karyopharm Therapeutics Inc Strategy Report
- Understand Karyopharm Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Karyopharm Therapeutics Inc (Karyopharm) focuses on the discovery, development and commercialization of novel drugs targeting nuclear transport for the treatment of cancer and other diseases. It also develops and markets novel small molecule selective inhibitors of nuclear export (SINE) compounds, a new class of drug candidates, which inhibit the nuclear export protein exportin 1 (XPO1) with a novel mechanism of action.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focuses on discovering new drugs and advancing its drug candidates for the treatment of multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, endometrial cancer, gynecologic malignancies, and glioblastoma multiforme, among other diseases. -In FY2022, it spent US$148.6 million on R&D activities. - The company's proprietary technology includes Selective Inhibitor of Nuclear Export (SINE) technology developed to address a fundamental mechanism of oncogenesis. -As of February 2023, the company had 32 patents in the US, 12 pending patent applications in the US, 112 granted patents and 92 pending patent applications outside the US applications filed under the Patent Cooperation Treaty.
Other Break-up
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer